Home » Stocks » ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR)

Stock Price: $69.29 USD 0.97 (1.42%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 7.15B
Revenue (ttm) 89.12M
Net Income (ttm) -109.59M
Shares Out 103.87M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $69.29
Previous Close $68.32
Change ($) 0.97
Change (%) 1.42%
Day's Open 67.83
Day's Range 66.83 - 69.54
Day's Volume 537,921
52-Week Range 32.86 - 93.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

This biotech underdog offers more than meets the eye.

1 week ago - The Motley Fool

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results

2 weeks ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 weeks ago - Business Wire

The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided ...

3 weeks ago - Forbes

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating.

3 weeks ago - Benzinga

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma (ccRCC).  ARO-HIF2 is the first tu...

3 weeks ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim results on RNAi investigational medicine ARO-HIF2 in patients with renal cell carcinoma

3 weeks ago - Business Wire

A paused clinical trial with an important asset wasn't what investors wanted to hear today.

4 weeks ago - The Motley Fool

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the company's investigational RNA interference (R...

4 weeks ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

4 weeks ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-ANG3 an RNAi therapeutic to treat mixed dyslipidemia

1 month ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Takeda presented positive clinical trial data on rare orphan disease RNAi drug ARO-AAT at EASL The International Liver Congress

1 month ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals presented preclinical data on the development of ARO-DUX4 at 28th Annual FSHD Society International Research Congress

1 month ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead presents data at EASL showing ARO-HSD reduces HSD17B13 mRNA and protein in the liver leading to reductions in ALT

1 month ago - Business Wire

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pa...

Other stocks mentioned: HZNP
1 month ago - Benzinga

PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO...

Other stocks mentioned: HZNP
1 month ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals dosed the first patient in a Phase 2b clinical study of ARO-APOC3 in patients with severe hypertriglyceridemia

1 month ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will present at multiple conferences in June 2021

1 month ago - Business Wire

Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1. Receipt of the option notice earns Arrowhead Pha...

Other stocks mentioned: JNJ
2 months ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals earns a $10 million option exercise fee from Janssen, part of Johnson & Johnson.

2 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals today announced financial results for its fiscal second quarter ended March 31, 2021.

2 months ago - Business Wire

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study evaluating ARO-AAT for rare genetic liver disease associated wi...

3 months ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Announces Improvement in Fibrosis after ARO-AAT, being co-developed with Takeda, in Patients with the rare genetic Alpha-1 Liver Disease

3 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

3 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $ARWR--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead's first muscle targeted investigational RNAi therapeutic candidate to ut...

3 months ago - Business Wire

In Q4 2020, we discussed why Arrowhead stock, a biopharmaceutical company that develops RNA interference therapies, looks attractive despite a stellar 16x move since early 2018. The stock has had a vola...

4 months ago - Forbes

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia

4 months ago - Business Wire

With the trading day about halfway over, the broad markets were trading sideways into the weekend.

Other stocks mentioned: BIIB, FTNT, KSS, PINS, DECK, INFI, IP ...
5 months ago - 24/7 Wall Street

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 566.67% over the past year to ($0.20)...

5 months ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reports fiscal 2021 first quarter earnings and holds a conference call

5 months ago - Business Wire

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NA...

6 months ago - GlobeNewsWire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia

6 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021

6 months ago - Business Wire

ARWR is a leading RNAi therapeutics company with a vast pipeline and a decade-long history of research. Often, companies with a long history of research find themselves unable to protect their Intellect...

7 months ago - Seeking Alpha

Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on InvestorPlace.

Other stocks mentioned: DD, IBM, INTC, TMO, ONTO, VECO
7 months ago - InvestorPlace

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

7 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited

8 months ago - Business Wire

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...

Other stocks mentioned: ADXS, ALNY
8 months ago - Benzinga

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) decreased 2.49% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36% over the past year...

8 months ago - Benzinga

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced financial results for its fiscal year ended September 30, 2020

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3

8 months ago - Business Wire

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings

8 months ago - Business Wire

These biotechs are fueling up for massive market launches.

Other stocks mentioned: CRSP
8 months ago - The Motley Fool

Despite a 3x growth since the March 18 lows of this year, at the current price of around $60 per share we believe Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interference the...

9 months ago - Forbes

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies th...

Other stocks mentioned: ALKS, NBIX, ACAD, BMRN, IONS
9 months ago - Forbes

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clin... [Read more...]

Industry
Biotechnology
IPO Date
Jun 16, 1993
CEO
Christopher Anzalone
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
ARWR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 89.31, which is an increase of 28.89% from the latest price.

Price Target
$89.31
(28.89% upside)
Analyst Consensus: Buy